[go: up one dir, main page]

CY1124657T1 - ΣΚΕΥΑΣΜΑΤΑ ΑΝΑΛΟΓΩΝ PTHrP, ΔΙΑΔΕΡΜΙΚΑ ΕΠΙΘΕΜΑΤΑ ΑΥTΩΝ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥTΩΝ - Google Patents

ΣΚΕΥΑΣΜΑΤΑ ΑΝΑΛΟΓΩΝ PTHrP, ΔΙΑΔΕΡΜΙΚΑ ΕΠΙΘΕΜΑΤΑ ΑΥTΩΝ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥTΩΝ

Info

Publication number
CY1124657T1
CY1124657T1 CY20211100636T CY211100636T CY1124657T1 CY 1124657 T1 CY1124657 T1 CY 1124657T1 CY 20211100636 T CY20211100636 T CY 20211100636T CY 211100636 T CY211100636 T CY 211100636T CY 1124657 T1 CY1124657 T1 CY 1124657T1
Authority
CY
Cyprus
Prior art keywords
formulations
patches
pthrp analog
bone
methods
Prior art date
Application number
CY20211100636T
Other languages
English (en)
Inventor
Gary Hattersley
Alan Harris
Jamal SAEH
Ehab Hamed
Kenneth Brown
Daniel Dohmeier
Ying Zhang
Lisa Dick
Joan Moseman
Original Assignee
Radius Health, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Health, Inc. filed Critical Radius Health, Inc.
Publication of CY1124657T1 publication Critical patent/CY1124657T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Αποκαλύπτονται σκευάσματα αναλόγου PTHrP για τη διαδερμική παροχή μίας θεραπευτικώς αποτελεσματικής ποσότητας ενός αναλόγου PTHrP, καθώς και διαδερμικά επιθέματα που παρασκευάζονται χρησιμοποιώντας αυτά τα σκευάσματα, μέθοδοι παρασκευής των αποκαλυπτομένων σκευασμάτων και επιθεμάτων, και μέθοδοι χρήσης αυτών των σκευασμάτων και επιθεμάτων για την αγωγή οστεοπόρωσης, οστεοπενίας, οστεοαρθρίτιδας, και/ή οστικών καταγμάτων, τη βελτίωση της οστικής πυκνότητας (BMD), τη βελτίωση της βαθμολογίας δοκιδωτού στού (TBS), και την αγωγή, πρόληψη, και/ή τον περιορισμό των οστικών καταγμάτων.
CY20211100636T 2015-10-09 2021-07-14 ΣΚΕΥΑΣΜΑΤΑ ΑΝΑΛΟΓΩΝ PTHrP, ΔΙΑΔΕΡΜΙΚΑ ΕΠΙΘΕΜΑΤΑ ΑΥTΩΝ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥTΩΝ CY1124657T1 (el)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562239801P 2015-10-09 2015-10-09
US201562239774P 2015-10-09 2015-10-09
US201562239773P 2015-10-09 2015-10-09
US201662324336P 2016-04-18 2016-04-18
US201662353249P 2016-06-22 2016-06-22
US201662396196P 2016-09-18 2016-09-18
PCT/US2016/056196 WO2017062922A1 (en) 2015-10-09 2016-10-08 Formulations of pthrp analogues, transdermal patches thereof, and uses thereof

Publications (1)

Publication Number Publication Date
CY1124657T1 true CY1124657T1 (el) 2022-07-22

Family

ID=58488710

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100636T CY1124657T1 (el) 2015-10-09 2021-07-14 ΣΚΕΥΑΣΜΑΤΑ ΑΝΑΛΟΓΩΝ PTHrP, ΔΙΑΔΕΡΜΙΚΑ ΕΠΙΘΕΜΑΤΑ ΑΥTΩΝ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥTΩΝ

Country Status (23)

Country Link
US (1) US20190091138A1 (el)
EP (2) EP3359241B1 (el)
JP (3) JP6867379B2 (el)
KR (1) KR20180067573A (el)
CN (2) CN115025068A (el)
AU (2) AU2016334378B2 (el)
BR (1) BR112018007159A2 (el)
CA (1) CA3000533C (el)
CY (1) CY1124657T1 (el)
DK (1) DK3359241T3 (el)
ES (1) ES2881461T3 (el)
HR (1) HRP20211127T1 (el)
HU (1) HUE055658T2 (el)
IL (2) IL287604B2 (el)
LT (1) LT3359241T (el)
MX (1) MX2018004192A (el)
PL (1) PL3359241T3 (el)
PT (1) PT3359241T (el)
RS (1) RS62394B1 (el)
SG (1) SG11201802871UA (el)
SI (1) SI3359241T1 (el)
SM (1) SMT202100411T1 (el)
WO (1) WO2017062922A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016226103A1 (en) * 2015-03-03 2017-08-31 Radius Health, Inc. Uses of PTHrP analogue in reducing fracture risk
AU2017253674B2 (en) 2016-04-18 2021-07-29 Kindeva Drug Delivery L.P. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
EP3685850A4 (en) * 2017-09-22 2021-06-16 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent pharmacodynamics and/or stability
CN107674113A (zh) * 2017-10-20 2018-02-09 广东医科大学 一种小分子活性肽及其制备方法、及采用该活性肽的透皮贴剂的制备方法与其用途
CN110054679B (zh) * 2018-01-18 2021-05-04 成都圣诺生物制药有限公司 一种合成Abaloparatide的方法
CN109602911B (zh) * 2019-01-09 2020-11-10 厦门大学 硫酸钙晶须或其组合物在制备皮肤促渗剂中的用途
TW202037378A (zh) 2019-02-28 2020-10-16 美商雷迪厄斯健康公司 用於遞送阿巴洛帕拉肽(abaloparatide)之經皮傳遞系統及使用方法
WO2021051082A1 (en) * 2019-09-12 2021-03-18 Radius Health, Inc. Methods of improving spinal fusion with abaloparatide
US12214216B1 (en) * 2019-10-16 2025-02-04 Helen Feng Photon enhanced bone growth system and method
WO2021149012A1 (en) 2020-01-24 2021-07-29 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
US12048543B2 (en) 2021-11-08 2024-07-30 Satio, Inc. Dermal patch for collecting a physiological sample with removable vial
US11877848B2 (en) 2021-11-08 2024-01-23 Satio, Inc. Dermal patch for collecting a physiological sample
US12029562B2 (en) 2021-04-14 2024-07-09 Satio, Inc. Dermal patch system
US11964121B2 (en) 2021-10-13 2024-04-23 Satio, Inc. Mono dose dermal patch for pharmaceutical delivery
US12178979B2 (en) 2021-10-13 2024-12-31 Satio, Inc. Dermal patch for delivering a pharmaceutical
US12053284B2 (en) 2021-11-08 2024-08-06 Satio, Inc. Dermal patch for collecting a physiological sample
US12214346B2 (en) 2021-10-13 2025-02-04 Satio, Inc. Dermal patch with a diagnostic test strip
US12023156B2 (en) 2021-10-13 2024-07-02 Satio, Inc. Dermal patch for collecting a physiological sample
EP4346878A1 (en) * 2021-05-25 2024-04-10 Radius Health, Inc. Treatment and prevention of osteoporosis in high body mass index individuals
WO2023281447A1 (en) 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event
CN119113134A (zh) * 2024-09-13 2024-12-13 南京羚诺生物医药技术研究院有限公司 一种提升阿巴帕肽半衰期的方法及其在治疗骨质疏松症中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032698A1 (en) * 2003-07-14 2005-02-10 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
CA2680690A1 (en) * 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
SI2957278T1 (sl) * 2006-10-03 2017-09-29 Radius Health, Inc. Stabilni sestavek, ki obsega PTHrP, in njegova uporaba
WO2009054988A1 (en) * 2007-10-23 2009-04-30 Alza Corporation Transdermal sustained release drug delivery
WO2010111617A2 (en) * 2009-03-27 2010-09-30 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
US20130041330A1 (en) * 2010-02-24 2013-02-14 Hisamitsu Pharmaceutical Co., Inc. Micro-needle device and preparation method
US8637458B2 (en) * 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
JP6033280B2 (ja) * 2011-04-22 2016-11-30 ラジウス ヘルス，インコーポレイテッド ＰＴＨ、ＰＴＨｒＰ、および関連ペプチドの薬剤送達方法
KR102143435B1 (ko) * 2011-11-30 2020-08-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 펩티드 치료제 및 아미노산을 포함하는 마이크로니들 장치 및 이의 제조 및 사용 방법
CN102526220A (zh) * 2012-01-10 2012-07-04 上海市中医医院 一种治疗期前收缩的中药贴剂及其制备方法和应用
US9581438B2 (en) * 2012-12-31 2017-02-28 General Electric Company Systems and methods for control of a non-destructive testing system
WO2015010092A1 (en) * 2013-07-18 2015-01-22 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
EP3359181A1 (en) * 2015-10-07 2018-08-15 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide drugs

Also Published As

Publication number Publication date
US20190091138A1 (en) 2019-03-28
SG11201802871UA (en) 2018-05-30
ES2881461T3 (es) 2021-11-29
JP7146011B2 (ja) 2022-10-03
EP3909566A1 (en) 2021-11-17
RS62394B1 (sr) 2021-10-29
WO2017062922A1 (en) 2017-04-13
SI3359241T1 (sl) 2021-11-30
IL287604B1 (en) 2023-12-01
PL3359241T3 (pl) 2021-12-20
IL287604A (en) 2021-12-01
JP2018536631A (ja) 2018-12-13
DK3359241T3 (da) 2021-07-19
HUE055658T2 (hu) 2021-12-28
IL287604B2 (en) 2024-04-01
EP3359241B1 (en) 2021-04-14
AU2016334378A1 (en) 2018-04-19
IL258441B (en) 2021-12-01
CN115025068A (zh) 2022-09-09
JP2021119141A (ja) 2021-08-12
EP3359241A1 (en) 2018-08-15
PT3359241T (pt) 2021-07-21
CA3000533A1 (en) 2017-04-13
CN108697881A (zh) 2018-10-23
MX2018004192A (es) 2018-09-26
CA3000533C (en) 2023-10-17
HRP20211127T1 (hr) 2021-10-15
SMT202100411T1 (it) 2021-11-12
JP2022174274A (ja) 2022-11-22
KR20180067573A (ko) 2018-06-20
AU2016334378B2 (en) 2021-12-02
LT3359241T (lt) 2021-10-11
BR112018007159A2 (pt) 2018-11-06
JP6867379B2 (ja) 2021-04-28
EP3359241A4 (en) 2019-06-26
AU2021269361A1 (en) 2021-12-16
IL258441A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
CY1124657T1 (el) ΣΚΕΥΑΣΜΑΤΑ ΑΝΑΛΟΓΩΝ PTHrP, ΔΙΑΔΕΡΜΙΚΑ ΕΠΙΘΕΜΑΤΑ ΑΥTΩΝ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥTΩΝ
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
PH12020550901A1 (en) Macrocyclic compounds for treating disease
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MY195427A (en) Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
PH12019501896A1 (en) Therapeutic dendrimers
MX2021006734A (es) Metodo para tratar el cancer.
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
NZ761519A (en) Nlrp3 modulators
EA201791560A1 (ru) Порошковый состав для интраназального введения для лечения гипогликемии
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
IL279208A (en) Therapeutic methods and compositions for the treatment of pancreatic cancer using 6, 8-bis(benzylsulfenyl)octanoic acid
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2020005557A (es) Agonistas de fxr para el tratamiento de enfermedades hepaticas.